1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% forward yield. Here's what ...
Betting Big On AbbVie: A Prescription For Growth And Dividends
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 (SNPINDEX ...
Indiatimes14 天
Numerology 101: A Simple Guide to Understanding Core Numbers
Numerology, the study of numbers and their connection to our lives, uses core numbers like Life Path, Expression, Soul Urge, Personality, and Birthday numbers to reveal insights into our ...
Seeking Alpha20 天
AbbVie: Upgrading To 'Strong Buy' After Pullback
Why is it necessary to pay attention to this franchise? The answer is quite simple and lies in the fact that sales of Humira, Skyrizi, and Rinvoq accounted for about 48% of its total revenue for ...
Yahoo20 天
J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
AbbVie also faced losses in sales for its blockbuster immunology drug Humira (adalimumab), when its US patent expired in ...
Yahoo Finance28 天
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 years the immunosuppressive drug has been on the market, it brought in ...